Laboratory testing for the new oral anticoagulants: A review of current practice

Pathology

Volumn 45, Issue 4, 2013, Pages 435-437

  Favaloro, Emmanuel J ^a   Bonar, Roslyn ^b   Butler, Jennifer ^c   Marsden, Katherine ^d  

^a WESTMEAD HOSPITAL   (Australia)

^b RCPA Haematology QAP   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

^d ROYAL HOBART HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879610542     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e328360f02d     Document Type: Article

References (13)

1. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants - the present and the future. Pathology 2011; 43: 682-92.
2. Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: For and against? Clin Chem Lab Med 2011; 49: 755-7.
3. Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochemia Medica 2012; 22: 329-41.
4. Cuker A. Unfractionated heparin for the treatment of venous thromboembolism: best practices and areas of uncertainty. Semin Thromb Hemost 2012; 38: 593-9.
5. Hughes S. Dabigatran: Australia issues bleeding warning. 7 Oct 2011; cited 19 Oct 2012. http://www.atrialfibrillation-au.org/files/file/News/ Dabigatran.pdf.
6. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-9.
7. Samama MM, Guinet C. Review: Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011; 49: 761-72.
8. Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012; 38: 16-22.
9. Lindahl TL, Baghaei F, Blixter IF, et al. Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in SwedenEffects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-8.
10. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-27.
11. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-97.
12. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost 2012; 38: 178-84.
13. Tripodi A, Di Iorio G, Lippi G, Testa S, Manotti C. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL. Clin Chem Lab Med 2012; 50: 137-40.